Regeneron Secures FDA Approval for Livsayis, an RNAi Therapy
The approval makes Livsayis the first RNAi therapeutic approved for generalized myasthenia gravis.
Story updates
12:01:11 PM UTC
SquawkNews
ALNYLAM COLLABORATOR REGENERON SECURES FDA APPROVAL OF LIVSAYIS™ (CEMDISIRAN), THE SEVENTH FDA-APPRO